Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of R/R Myeloma

Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of R/R Myeloma (March 2021)

Monday, March 8, 2021
Webinar -- 12:00 PM ET
https://www.clinicaloptions.com/MyelomaConvo2021Join1

Agenda

Welcome and Introduction

Contemporary Management of R/R MM
Discussion of current treatment options and considerations for sequencing available therapies

Emerging Therapies Targeting BCMA in R/R MM
Comparing the various modalities of BCMA-targeted therapies, including current efficacy, safety, and administration.

Other Novel Agents and New Targets for MM
Expert views on the future of myeloma care, with clinical trial spotlight and discussion of early data

Final Thoughts

Faculty

Program Director
Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Faculty
Saad Z. Usmani, MD, MBA, FACP

Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

Suzanne Lentzsch, MD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Goal Statement
The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals about the recent developments in the care of relapsed/refractory multiple myeloma and incorporating new data and new therapies into their patient treatment plans.

Target Audience
This educational program is intended for hematologists, oncologists, and other healthcare providers who care for patients with relapsed/refractory multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Incorporate new and emerging therapies into treatment plans for patients with R/R MM based on available data and individual patient and disease characteristics
  • Manage toxicities associated with CAR T-cell therapy and BCMA-targeted therapies in patients with R/R MM
  • Evaluate ongoing major clinical trials investigating novel therapeutic approaches in R/R MM

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.